Regencell Bioscience Holdings (RGC) Receivables - Other (2020 - 2022)

Regencell Bioscience Holdings has reported Receivables - Other for 3 years, with the latest figure at $10561.0 in Q2 2022.

• For the quarter ending Q2 2022, Receivables - Other fell 99.71% year-over-year to $10561.0; the trailing twelve-month figure through Jun 2022 stood at $10561.0 (down 99.71% YoY), and the FY2022 full-year result was $10561.0, down 99.71% from the prior year.
• Receivables - Other for Q2 2022 stood at $10561.0, down from $3.7 million in the prior quarter.
• The five-year high for Receivables - Other was $3.7 million in Q2 2021, with the low at $10561.0 in Q2 2022.
• Historically, Receivables - Other has averaged $2.3 million across 3 years, with a median of $3.1 million in 2020.
• Annual changes were most pronounced in 2021 — Receivables - Other grew 19.87% — and 2022, when it tumbled 99.71%.
• Regencell Bioscience Holdings' Receivables - Other stood at $3.1 million in 2020, then gained by 19.87% to $3.7 million in 2021, then plunged by 99.71% to $10561.0 in 2022.
• The last three Receivables - Other figures came in at $10561.0 (Q2 2022), $3.7 million (Q2 2021), and $3.1 million (Q2 2020), per Business Quant data.